These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 32019702)
1. Application of a cost-effectiveness analysis of pathogen-specific vaccines against gastroenteritis to a military population in a developing country setting. Ballard SB; Tallant A; Guerra RG; Quigley D; Stiegmann R; Mirelman AJ; Riddle MS; Gilman RH; Vaccine; 2020 Feb; 38(10):2292-2297. PubMed ID: 32019702 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of norovirus vaccination in children in Peru. Mirelman AJ; Ballard SB; Saito M; Kosek MN; Gilman RH Vaccine; 2015 Jun; 33(27):3084-91. PubMed ID: 25980428 [TBL] [Abstract][Full Text] [Related]
3. Relative cost-effectiveness of a norovirus vaccine in the deployed military setting compared to a vaccine against Campylobacter sp., ETEC, and Shigella sp. Tallant A; Porter CK; Putnam SD; Tribble DR; Hooper TI; Riddle MS Vaccine; 2014 Sep; 32(40):5156-62. PubMed ID: 25086264 [TBL] [Abstract][Full Text] [Related]
4. Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae. O'Ryan M; Vidal R; del Canto F; Salazar JC; Montero D Hum Vaccin Immunother; 2015; 11(3):584-600. PubMed ID: 25715048 [TBL] [Abstract][Full Text] [Related]
5. Global Economic Burden of Norovirus Gastroenteritis. Bartsch SM; Lopman BA; Ozawa S; Hall AJ; Lee BY PLoS One; 2016; 11(4):e0151219. PubMed ID: 27115736 [TBL] [Abstract][Full Text] [Related]
6. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595 [TBL] [Abstract][Full Text] [Related]
7. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rheingans RD; Constenla D; Antil L; Innis BL; Breuer T Rev Panam Salud Publica; 2007 Apr; 21(4):205-16. PubMed ID: 17612464 [TBL] [Abstract][Full Text] [Related]
8. Incidence of Norovirus-Associated Medical Encounters among Active Duty United States Military Personnel and Their Dependents. Rha B; Lopman BA; Alcala AN; Riddle MS; Porter CK PLoS One; 2016; 11(4):e0148505. PubMed ID: 27115602 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model. Patel HD; Roberts ET; Constenla DO Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497 [TBL] [Abstract][Full Text] [Related]
10. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Plosker GL Pharmacoeconomics; 2011 Nov; 29(11):989-1009. PubMed ID: 21988293 [TBL] [Abstract][Full Text] [Related]
11. Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies. Hungerford D; Smith K; Tucker A; Iturriza-Gómara M; Vivancos R; McLeonard C; A Cunliffe N; French N BMC Infect Dis; 2017 Aug; 17(1):569. PubMed ID: 28810833 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252 [TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries. Plosker GL Paediatr Drugs; 2012 Dec; 14(6):429-33. PubMed ID: 23013458 [TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of a pentavalent rotavirus vaccine in Oman. Al Awaidy ST; Gebremeskel BG; Al Obeidani I; Al Baqlani S; Haddadin W; O'Brien MA BMC Infect Dis; 2014 Jun; 14():334. PubMed ID: 24941946 [TBL] [Abstract][Full Text] [Related]
15. Vaccines against gastroenteritis, current progress and challenges. Seo H; Duan Q; Zhang W Gut Microbes; 2020 Nov; 11(6):1486-1517. PubMed ID: 32552414 [TBL] [Abstract][Full Text] [Related]
16. Strategies to Improve Management of Acute Watery Diarrhea during a Military Deployment: A Cost Effectiveness Analysis. Schrader AJ; Tribble DR; Riddle MS Am J Trop Med Hyg; 2017 Dec; 97(6):1857-1866. PubMed ID: 29016296 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana. Abbott C; Tiede B; Armah G; Mahmoud A Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664 [TBL] [Abstract][Full Text] [Related]
18. The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control. Lopman BA; Steele D; Kirkwood CD; Parashar UD PLoS Med; 2016 Apr; 13(4):e1001999. PubMed ID: 27115709 [TBL] [Abstract][Full Text] [Related]
19. Measuring indirect effects of rotavirus vaccine in low income countries. Bennett A; Bar-Zeev N; Cunliffe NA Vaccine; 2016 Aug; 34(37):4351-3. PubMed ID: 27443593 [TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of typhoid fever vaccines in US military personnel. Warren TA; Finder SF; Brier KL; Ries AJ; Weber MP; Miller MR; Potyk RP; Reeves CS; Moran EL; Tornow JJ Pharmacoeconomics; 1996 Nov; 10(5):475-83. PubMed ID: 10163629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]